23-29 September 2017
These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts
Disease modifying drugs - early vs escalation trial
Nottingham will be one of eight UK centres taking part of the trial to compare approaches to treatment with disease modifying drugs (DMDs). Participants will be people recently diagnosed with MS. One group will start treatment with one of the more powerful DMDs, the other will start with a less powerful drug and switch to a different DMD if that proves ineffective.
Source: Nottingham Post
MS Trust link: MS Decisions - a guide to the disease modifying drugs
Moves to reclassify pregabalin and gabapentin
The government is to hold a consultation on whether to make gabapentinoids controlled drugs. If the change goes ahead, people would not be able to get pregabalin and gabapentin on repeat prescription. The move prompted by a sharp increase in deaths linked to the misuse of the drugs.
Links between cognition and mobility
US research has looked that the time it took someone with mobility problems due to MS to do the Timed Up and Go test. The time taken increased when they were asked to do a cognitive task, such as reciting the alphabet of doing simple arithmetic, at the same time. This may have implications for everyday tasks that involve both physical and cognitive activity.
Source: Neurology Reviews
MS Trust link: Cognition and cognitive symptoms
Lemtrada remains effective over five years
A study of people who had been taking Lemtrada (alemtuzumab) for five years found that relapse rates remained low, that four of five people showed no progression and that a third had seen some improvement in disability scores. These results are largely in line with previous follow up analyses
Source: Multiple Sclerosis Advisor
MS Trust link: Lemtrada (alemtuzumab)